Drug Type Antibody toxin conjugate |
Synonyms MT-2274, MT-4019, MT-6020 + [3] |
Target |
Mechanism CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | US | 01 Jul 2017 |